Core competency across biosimilar and plasma derived products makes Intas’ Biologics Business Unit one of its fastest growing franchise. Keeping patient’s welfare and wellbeing at the forefront, since the year 2000 it has been developing bio-therapeutics that meet the highest quality standards, and making them available at affordable prices.
Leveraging its R&D strengths and state-of-the-art manufacturing facilities, Intas’ Biologics BU has been focused on developing high quality recombinant DNA protein (rDNA) products and plasma derived products to address unmet medical needs across various therapeutics areas such as Oncology (Cancer), Auto-Immune, Ophthalmology, Nephrology, and Plasma derived product based therapies.
Intas’ R&D capabilities and a pool of Scientists from world class institutes across the globe, coupled with cutting edge technology platform and know-how has made it possible to build a robust yet niche product portfolio consist of 11 commercialized products, 8 rDNA products including 1 monoclonal antibody, and 3 plasma derived products. In addition the company has as on date 12 products in its pipeline. In addition several products are exported to many countries under various distribution and licensing agreements.
Being first is a norm at Intas Biologics, with a rich product portfolio of biosimilars across microbial and mammalian cell culture products like Neukine® (GCSF), Erykine® (EPO), Intalfa® (IFN), Pegasta® (Peg GCSF), Terifrac® (Teriparatide), Mabtas® (Rituximab), Folisurge® (FSH) which are testament to its innovative expertise. It is India’s first biosimilars manufacturing unit to receive European Union - Good Manufacturing Practice (EU-GMP) certification for the Drug Substance (microbial) and Drug Product manufacturing facilities, attesting to highest quality of manufacturing and quality systems. In addition to the EU-GMP, Intas’ Biological BU facilities are approved by various other regulatory agencies such as ANVISA, GCC, MCC, Indonesia, etc.
Biosimilar Pipeline - Intas Biologics
Intas has several strategic marketing alliances and out-licensing collaborations with reputed International companies across both Regulated and Emerging pharmaceutical markets, such as Europe, China, S E Asia, Middle East, Russia & CIS, South & Central America and Africa. Intas endeavors to offer high quality yet affordable therapies globally.
Intas’ biosimilar are registered in more than 22 countries, and under registration in more than 25 countries, through strategic marketing alliances.
Three of Intas’ biosimilar assets are already partnered for the EU, US, Canada, China and other markets. The first product for the regulated markets will be GCSF and is expected to be launched in Europe towards the end of 2013 by its collaborator. Intas aims to be first Indian company to have enabled a commercialization of an indigenously developed biosimilar product in the regulated market.
Several other biosimilar programs are at advance stage of development, and available for partnering discussions.
Plasma Derived Products
Intas also operates in the field of Plasma derived products and therapies with proven technical capabilities. The current product portfolio has 3 products and there are several others under development.
For more information, please write to